$1.45
-0.01-0.68%
At close: Nov 13, 4:00 PM EST
$1.44
-0.0072-0.5%
After Hours: 5:10 PM EST
Acrivon Therapeutics Inc
ACRVNASDAQ
Acrivon Therapeutics fell 30.0% from $2.07 to $1.45, behind the S&P 500's +12.3%. Its worst day was Jan 8 (−34.6%), and its low came Mar 30 at $1.29.
Nov 13, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.47 beat the $-0.58 estimate on $0.00 revenue.
+8.2% · S&P 500 0.0%
Acrivon Therapeutics closed at its highest level of the year, 45.4% above where the year started.
Story events cover the past 12 months · Times ET
+31.4%, the year's best day · S&P 500 +0.6%
Acrivon Therapeutics shares fell 17.9%, while the S&P 500 fell 0.5%.
−17.9% · S&P 500 −0.5%
EPS of $-0.49 missed the $-0.47 estimate on $0.00 revenue (est. $541,598.00).
+3.7% · S&P 500 −0.5%
Acrivon Therapeutics closed at its lowest level of the year, 37.7% below where the year started.
−3.0% · S&P 500 −0.3%
EPS of $-0.49 beat the $-0.51 estimate on $0.00 revenue (est. $498,304.00).
0.0% · S&P 500 +0.8%
EPS of $-0.43 beat the $-0.50 estimate on $0.00 revenue (est. $464,000.00).
+7.6% · S&P 500 +0.7%
Where it ended: a close of $1.45 on Nov 13, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.44, revenue est. $606,000.00).
Nothing in the past 12 months.
All ACRV dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ACRV and SPY from Benzinga historical bars. Not investment advice.
